Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

BACKGROUND: Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). In this population, polypharmacy for a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal, Zurth, Christian, Fricke, Robert, Gieschen, Hille, Graudenz, Kristina, Koskinen, Mikko, Ploeger, Bart, Moss, Jonathan, Prien, Olaf, Borghesi, Gustavo, Petrenciuc, Oana, Tammela, Teuvo L., Kuss, Iris, Verholen, Frank, Smith, Matthew R., Fizazi, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797643/
https://www.ncbi.nlm.nih.gov/pubmed/31571095
http://dx.doi.org/10.1007/s11523-019-00674-0

Ejemplares similares

Ejemplares similares